Cargando…
Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
OBJECTIVE: Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. METHODS: The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Me...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591656/ https://www.ncbi.nlm.nih.gov/pubmed/34758674 http://dx.doi.org/10.1177/03000605211046173 |
_version_ | 1784599298545025024 |
---|---|
author | Fan, Bijun Tan, Xiaoming Lou, Yueyan Zheng, Yu Zhang, Liyan Wu, Xueling |
author_facet | Fan, Bijun Tan, Xiaoming Lou, Yueyan Zheng, Yu Zhang, Liyan Wu, Xueling |
author_sort | Fan, Bijun |
collection | PubMed |
description | OBJECTIVE: Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. METHODS: The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Medicine, Shanghai Jiaotong University were retrospectively reviewed. The optimal cutoff prognostic nutritional index (PNI) value for predicting efficacy was determined according to receiver operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were calculated and compared using the Kaplan–Meier method and log‐rank test. The prognostic values of each variable were evaluated with univariate and multivariate Cox proportional hazard regression analyses. RESULTS: The overall disease control rate of 44 patients with lung cancer was 93.2% (41/44). The median PFS was 5.0 months (95% [confidence interval] CI: 2.2–7.8), and the median OS was 6.5 months (95% CI: 3.6–9.3). The multivariate analysis results indicated that hand–foot syndrome and high PNI values were independent protective factors of PFS and OS. CONCLUSIONS: Anlotinib was effective in treating locally advanced or advanced lung cancer. High pretreatment PNI scores and the presence of hand–foot syndrome after treatment were independent prognostic markers for favorable OS and PFS. |
format | Online Article Text |
id | pubmed-8591656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-85916562021-11-16 Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study Fan, Bijun Tan, Xiaoming Lou, Yueyan Zheng, Yu Zhang, Liyan Wu, Xueling J Int Med Res Retrospective Clinical Research Report OBJECTIVE: Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. METHODS: The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Medicine, Shanghai Jiaotong University were retrospectively reviewed. The optimal cutoff prognostic nutritional index (PNI) value for predicting efficacy was determined according to receiver operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were calculated and compared using the Kaplan–Meier method and log‐rank test. The prognostic values of each variable were evaluated with univariate and multivariate Cox proportional hazard regression analyses. RESULTS: The overall disease control rate of 44 patients with lung cancer was 93.2% (41/44). The median PFS was 5.0 months (95% [confidence interval] CI: 2.2–7.8), and the median OS was 6.5 months (95% CI: 3.6–9.3). The multivariate analysis results indicated that hand–foot syndrome and high PNI values were independent protective factors of PFS and OS. CONCLUSIONS: Anlotinib was effective in treating locally advanced or advanced lung cancer. High pretreatment PNI scores and the presence of hand–foot syndrome after treatment were independent prognostic markers for favorable OS and PFS. SAGE Publications 2021-11-10 /pmc/articles/PMC8591656/ /pubmed/34758674 http://dx.doi.org/10.1177/03000605211046173 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Retrospective Clinical Research Report Fan, Bijun Tan, Xiaoming Lou, Yueyan Zheng, Yu Zhang, Liyan Wu, Xueling Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study |
title | Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study |
title_full | Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study |
title_fullStr | Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study |
title_full_unstemmed | Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study |
title_short | Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study |
title_sort | prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study |
topic | Retrospective Clinical Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591656/ https://www.ncbi.nlm.nih.gov/pubmed/34758674 http://dx.doi.org/10.1177/03000605211046173 |
work_keys_str_mv | AT fanbijun prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy AT tanxiaoming prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy AT louyueyan prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy AT zhengyu prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy AT zhangliyan prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy AT wuxueling prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy |